This Research Paper explores decisions by the National Institute for Health and Care Excellence (NICE) that new technologies are to be recommended in line with clinical practice (RiLCP). The authors qualitatively assess documentation associated with RiLCP decisions to create a framework to describe common themes, and assess the level of patient access associated with each RiLCP decision.
Garau, M., Marsden, G., Devlin, N., Amedeo Mazzanti, N. and Profico, A.
Published paper using MCDA to obtain preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and to assess the value of obinutuzumab for rituximab-refractory iNHL.
Fischer, A., Hernandez-Villafuerte, K., Latimer, N., and Henshall, C.
This Research Paper reports on a literature review of trials using PFS as a surrogate for OS in oncology between 2012 and 2016; a workshop and interviews involving people from a regulatory agency (EMA) a “payer” organisation (NICE), academics, and from the member organisations comprising POI; and critiques of statistical modelling and economic analysis approaches to surrogacy.
Barnsley, P., Cubi-Molla, P., Fischer, A., and Towse, A.
The quality of decision-making in key public sector bodies dealing with resource allocation is a major determinant of their efficiency. One of the most difficult and contentious areas of decision-making is the way that uncertainty is dealt with.
Feng, Y., Devlin, N., Bateman, A., Zamora, B., and Parkin, D.
EQ-5D data are often summarised by an EQ-5D index, whose distribution for its original version, the EQ-5D-3L, often shows two distinct groups in patient populations, arising from both the distribution of ill health and how the index is constructed. To date, there is little evidence about the distribution of the EQ-5D-5L index. This project aims to:
Cole, A., Lundqvist, A., Lorgelly, P., Norrlid, H., Karlsberg Schaffer, S., Lewis, F., Hernandez-Villafuerte, K., Lindgren, P., Garau, M., Welin, K-O., Bianchi, S., Althin, R., O’Neill, P., Persson, U., and Towse, A.
The economic burden that cancer poses on our society is staggering – 25 million years of healthy life lost, at cost of €126 billion including €52 billion in lost productivity – and continues to grow with the ageing of the population. It is imperative, in light of growing financial pressures on our health care systems, that we find ways to make the best use of available resources to deliver high quality cancer care to patients.
Marsden, G., Martin, A., Zamora, B., Exley, J., Sussex, J. and Towse, A.
The Oxford Academic Health Science Network (Oxford AHSN) wishes to demonstrate the value of the various projects and programmes that the network has developed and implemented since it was established in 2013.
Cole, A., Marsden, G., Devlin, N., Grainger, D., Lee, E.K. and Oortwijn, W.
This report provides a detailed summary of a panel session which took place at the HTAi 2016 annual meeting in Tokyo. The panel session was entitled "New Age Decision Making in HTA: Is It Applicable in Asia?". To open the session, David Grainger (Eli Lilly & Company) provided an overview of the session, offering useful background information on the topic.
Cole, A., Chan, A., Mujoomdar, M., Pichler, F. and Towse, A.
This report provides a detailed summary of a panel session which took place at the HTAi 2016 annual meeting, Tokyo. The panel session was entitled "How Can HTA in Asia-Pacific Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?" and was chaired by Franz Pichler (Eli Lilly & Company).